Whyte, S., Pandor, A. and Stevenson, M. (2012) Bevacizumab for Metastatic Colorectal Cancer: A NICE Single Technology Appraisal. Pharmacoeconomics, 30, 1119-1132.
 Mailliez, A., et al. (2010) Nasal Septum Perforation: A Side Effect of Bevacizumab Chemotherapy in Breast Cancer Patients. British Journal of Cancer, 103, 772-775.
 Ramiscal, J.A. and Jatoi, A. (2011) Bevacizumab-Induced Nasal Septal Perforation: Incidence of Symptomatic, Confirmed Event(s) in Colorectal Cancer Patients. Acta Oncologica, 50, 578-581.
 Hapani, S., Chu, D. and Wu, S. (2009) Risk of Gastrointestinal Perforation in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis. The Lancet Oncology, 10, 559-568.
 Hompes, D. and Ruers, T. (2011) Review: Incidence and Clinical Significance of Bevacizumab-Related Non-Surgical and Surgical Serious Adverse Events in Metastatic Colorectal Cancer. European Journal of Surgical Oncology (EJSO), 37, 737-746.
 Van Cutsem, E., et al. (2009) Safety and Efficacy of First-Line Bevacizumab with FOLFOX, XELOX, FOLFIRI and Fluoropyrimidines in Metastatic Colorectal Cancer: The BEAT Study. Annals of Oncology, 20, 1842-1847.
 Kozloff, M., et al. (2009) Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study. The Oncologist, 14, 862-870.
 Poultsides, G.A., et al. (2009) Outcome of Primary Tumor in Patients with Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy without Surgery as Initial Treatment. Journal of Clinical Oncology, 27, 3379-3384. http://dx.doi.org/10.1200/JCO.2008.20.9817